Condensed Consolidated Financial Information for Guarantor Subsidiaries and Non-Guarantor Subsidiaries - Condensed Consolidating Statement of Cash Flows (Detail) (USD $) | 12 Months Ended |
In Thousands, unless otherwise specified | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 |
Schedule Of Condensed Consolidating Statement Of Cash Flows [Line Items] | | | |
Net cash provided by operating activities | $489,452 | $506,920 | $468,229 |
Cash flows from investing activities: | | | |
Acquisitions | -35,192 | -983 | -769,513 |
Net of cash acquired from acquisitions | 304 | 0 | 36,113 |
Purchase of non-controlling interest in non-public companies | -5,000 | 0 | -2,250 |
Earnout payments | 0 | 0 | -250 |
Escrow funding associated with acquisitions | 0 | 0 | -38,800 |
Proceeds from release of acquisition related escrows | 0 | 280 | 1,455 |
Proceeds from sale of subsidiary | 151,170 | 0 | 0 |
Investment in subsidiaries | 0 | 0 | |
Intercompany dividends received from subsidiaries | 0 | | |
Repayments received from other subsidiaries | 0 | | |
Repayments received from other subsidiaries | | 0 | 0 |
Advances provided to other subsidiaries | 0 | 0 | 0 |
Capital expenditures | -146,818 | -145,976 | -74,373 |
Purchases of available-for-sale securities | -203 | -5,870 | -1,784 |
Proceeds from sales and maturities of available-for-sale securities | 513 | 7,484 | 1,932 |
Other investing activities, net | 0 | -561 | 0 |
Net cash used in investing activities | -35,530 | -145,626 | -883,583 |
Cash flows from financing activities: | | | |
Repayments of current portion of long-term debt | 0 | -180,000 | 0 |
Proceeds from issuance of long-term debt, net of original issue discount | 0 | 0 | 347,224 |
Repayments of short-term debt refinanced on a long-term basis | 0 | 0 | -347,224 |
Proceeds (repayments) from short-term debt, net | 160,000 | -10,000 | 357,224 |
Proceeds from issuance of intercompany common stock | 0 | 0 | |
Intercompany dividends paid to subsidiaries | 0 | | |
Transfer of cash due to the Verisk Health, Inc. merger | | 0 | |
Repayments of advances to other subsidiaries | 0 | 0 | |
Advances received from other subsidiaries | 0 | 0 | 0 |
Payment of debt issuance costs | -465 | -605 | -3,905 |
Repayments of advances provided to other subsidiaries | | | 0 |
Excess tax benefits from exercised stock options | 22,566 | 109,946 | 60,672 |
Proceeds from stock options exercised | 24,648 | 80,368 | 68,388 |
Net share settlement of taxes from restricted stock awards | -1,625 | 0 | 0 |
Other financing activities, net | -5,718 | -6,770 | -6,549 |
Net cash (used in) provided by financing activities | -579,078 | -284,472 | 313,555 |
Effect of exchange rate changes | -1,286 | -840 | 15 |
(Decrease) increase in cash and cash equivalents | -126,442 | 75,982 | -101,784 |
Cash and cash equivalents, beginning of period | 165,801 | 89,819 | 191,603 |
Cash and cash equivalents, end of period | 39,359 | 165,801 | 89,819 |
Supplemental disclosures: | | | |
Increase in intercompany balances form the purchase of MediConnect and Argus by ISO | | | 0 |
Increase in intercompany balances from the purchase of treasury stock by Verisk funded directly by ISO | 0 | 0 | 0 |
Increase in intercompany balances from proceeds received by ISO related to issuance of Verisk common stock from options exercised | 0 | 0 | 0 |
Verisk Class A [Member] | | | |
Cash flows from financing activities: | | | |
Repurchases of Class A common stock | -778,484 | -277,411 | -162,275 |
Verisk Analytics, Inc. [Member] | | | |
Schedule Of Condensed Consolidating Statement Of Cash Flows [Line Items] | | | |
Net cash provided by operating activities | 104 | 42 | -20,115 |
Cash flows from investing activities: | | | |
Acquisitions | 0 | 0 | 0 |
Purchase of non-controlling interest in non-public companies | 0 | | -250 |
Earnout payments | | | 0 |
Escrow funding associated with acquisitions | | | 0 |
Proceeds from release of acquisition related escrows | | 66 | 0 |
Proceeds from sale of subsidiary | 0 | | |
Investment in subsidiaries | 0 | 0 | |
Intercompany dividends received from subsidiaries | 0 | | |
Repayments received from other subsidiaries | 20,000 | | |
Repayments received from other subsidiaries | | 0 | 19,400 |
Advances provided to other subsidiaries | 0 | -30,000 | 0 |
Capital expenditures | 0 | 0 | 0 |
Purchases of available-for-sale securities | 0 | 0 | 0 |
Proceeds from sales and maturities of available-for-sale securities | 0 | 0 | 0 |
Other investing activities, net | | 0 | |
Net cash used in investing activities | 20,000 | -29,934 | 19,150 |
Cash flows from financing activities: | | | |
Repayments of current portion of long-term debt | | 0 | |
Proceeds from issuance of long-term debt, net of original issue discount | | | 347,224 |
Repayments of short-term debt refinanced on a long-term basis | | | 0 |
Proceeds (repayments) from short-term debt, net | 0 | 0 | 0 |
Proceeds from issuance of intercompany common stock | 0 | 0 | |
Intercompany dividends paid to subsidiaries | 0 | | |
Transfer of cash due to the Verisk Health, Inc. merger | | 0 | |
Repayments of advances to other subsidiaries | -40,000 | -10,010 | |
Advances received from other subsidiaries | 0 | 60,000 | 0 |
Payment of debt issuance costs | 0 | 0 | -2,557 |
Repayments of advances provided to other subsidiaries | | | -419,812 |
Excess tax benefits from exercised stock options | 0 | 0 | 0 |
Proceeds from stock options exercised | 0 | 0 | 0 |
Net share settlement of taxes from restricted stock awards | 0 | | |
Other financing activities, net | 0 | 0 | 0 |
Net cash (used in) provided by financing activities | -40,000 | 49,990 | -75,145 |
Effect of exchange rate changes | 0 | 0 | 0 |
(Decrease) increase in cash and cash equivalents | -19,896 | 20,098 | -76,110 |
Cash and cash equivalents, beginning of period | 20,226 | 128 | 76,238 |
Cash and cash equivalents, end of period | 330 | 20,226 | 128 |
Supplemental disclosures: | | | |
Increase in intercompany balances form the purchase of MediConnect and Argus by ISO | | | 17,000 |
Increase in intercompany balances from the purchase of treasury stock by Verisk funded directly by ISO | 778,484 | 277,411 | 162,275 |
Increase in intercompany balances from proceeds received by ISO related to issuance of Verisk common stock from options exercised | 24,648 | 80,368 | 68,388 |
Increase (decrease) in intercompany balances due to the merger of Verisk Health, Inc. | | 0 | |
Verisk Analytics, Inc. [Member] | Verisk Class A [Member] | | | |
Cash flows from financing activities: | | | |
Repurchases of Class A common stock | 0 | 0 | 0 |
Guarantor Subsidiaries [Member] | | | |
Schedule Of Condensed Consolidating Statement Of Cash Flows [Line Items] | | | |
Net cash provided by operating activities | 336,094 | 287,956 | 329,845 |
Cash flows from investing activities: | | | |
Acquisitions | -5,051 | -983 | -762,596 |
Purchase of non-controlling interest in non-public companies | -5,000 | | -2,000 |
Earnout payments | | | 0 |
Escrow funding associated with acquisitions | | | -38,000 |
Proceeds from release of acquisition related escrows | | 214 | 1,455 |
Proceeds from sale of subsidiary | 151,170 | | |
Investment in subsidiaries | -30,609 | -350 | |
Intercompany dividends received from subsidiaries | 114 | | |
Repayments received from other subsidiaries | 224,447 | | |
Repayments received from other subsidiaries | | 206,282 | 592,356 |
Advances provided to other subsidiaries | -5,075 | -68,692 | -52,000 |
Capital expenditures | -124,513 | -118,307 | -60,525 |
Purchases of available-for-sale securities | -203 | -5,870 | -1,784 |
Proceeds from sales and maturities of available-for-sale securities | 513 | 7,484 | 1,932 |
Other investing activities, net | | -561 | |
Net cash used in investing activities | 205,793 | 19,217 | -321,162 |
Cash flows from financing activities: | | | |
Repayments of current portion of long-term debt | | -180,000 | |
Proceeds from issuance of long-term debt, net of original issue discount | | | 0 |
Repayments of short-term debt refinanced on a long-term basis | | | -347,224 |
Proceeds (repayments) from short-term debt, net | 160,000 | -10,000 | 357,224 |
Proceeds from issuance of intercompany common stock | 0 | 0 | |
Intercompany dividends paid to subsidiaries | 0 | | |
Transfer of cash due to the Verisk Health, Inc. merger | | 2,877 | |
Repayments of advances to other subsidiaries | -39,289 | -9,605 | |
Advances received from other subsidiaries | 0 | 30,000 | 0 |
Payment of debt issuance costs | -465 | -605 | -1,348 |
Repayments of advances provided to other subsidiaries | | | -19,400 |
Excess tax benefits from exercised stock options | 22,566 | 109,946 | 60,672 |
Proceeds from stock options exercised | 24,648 | 80,368 | 68,388 |
Net share settlement of taxes from restricted stock awards | -1,625 | | |
Other financing activities, net | -5,613 | -6,478 | -5,931 |
Net cash (used in) provided by financing activities | -618,262 | -260,908 | -49,894 |
Effect of exchange rate changes | -589 | -741 | -31 |
(Decrease) increase in cash and cash equivalents | -76,964 | 45,524 | -41,242 |
Cash and cash equivalents, beginning of period | 81,095 | 35,571 | 76,813 |
Cash and cash equivalents, end of period | 4,131 | 81,095 | 35,571 |
Supplemental disclosures: | | | |
Increase in intercompany balances form the purchase of MediConnect and Argus by ISO | | | 790,174 |
Increase in intercompany balances from the purchase of treasury stock by Verisk funded directly by ISO | 778,484 | 277,411 | 162,275 |
Increase in intercompany balances from proceeds received by ISO related to issuance of Verisk common stock from options exercised | 24,648 | 80,368 | 68,388 |
Increase (decrease) in intercompany balances due to the merger of Verisk Health, Inc. | | 85,953 | |
Guarantor Subsidiaries [Member] | Verisk Class A [Member] | | | |
Cash flows from financing activities: | | | |
Repurchases of Class A common stock | -778,484 | -277,411 | -162,275 |
Non-Guarantor Subsidiaries [Member] | | | |
Schedule Of Condensed Consolidating Statement Of Cash Flows [Line Items] | | | |
Net cash provided by operating activities | 153,254 | 218,922 | 158,499 |
Cash flows from investing activities: | | | |
Acquisitions | -30,141 | 0 | -6,917 |
Purchase of non-controlling interest in non-public companies | 0 | | 0 |
Earnout payments | | | -250 |
Escrow funding associated with acquisitions | | | -800 |
Proceeds from release of acquisition related escrows | | 0 | 0 |
Proceeds from sale of subsidiary | 0 | | |
Investment in subsidiaries | 0 | 0 | |
Intercompany dividends received from subsidiaries | 0 | | |
Repayments received from other subsidiaries | 19,289 | | |
Repayments received from other subsidiaries | | 9,605 | 0 |
Advances provided to other subsidiaries | 0 | 0 | 0 |
Capital expenditures | -22,305 | -27,669 | -13,848 |
Purchases of available-for-sale securities | 0 | 0 | 0 |
Proceeds from sales and maturities of available-for-sale securities | 0 | 0 | 0 |
Other investing activities, net | | 0 | |
Net cash used in investing activities | -33,157 | -18,064 | -21,815 |
Cash flows from financing activities: | | | |
Repayments of current portion of long-term debt | | 0 | |
Proceeds from issuance of long-term debt, net of original issue discount | | | 0 |
Repayments of short-term debt refinanced on a long-term basis | | | 0 |
Proceeds (repayments) from short-term debt, net | 0 | 0 | 0 |
Proceeds from issuance of intercompany common stock | 30,609 | 350 | |
Intercompany dividends paid to subsidiaries | -114 | | |
Transfer of cash due to the Verisk Health, Inc. merger | | -2,877 | |
Repayments of advances to other subsidiaries | -184,447 | -196,272 | |
Advances received from other subsidiaries | 5,075 | 8,692 | 52,000 |
Payment of debt issuance costs | 0 | 0 | 0 |
Repayments of advances provided to other subsidiaries | | | -172,544 |
Excess tax benefits from exercised stock options | 0 | 0 | 0 |
Proceeds from stock options exercised | 0 | 0 | 0 |
Net share settlement of taxes from restricted stock awards | 0 | | |
Other financing activities, net | -105 | -292 | -618 |
Net cash (used in) provided by financing activities | -148,982 | -190,399 | -121,162 |
Effect of exchange rate changes | -697 | -99 | 46 |
(Decrease) increase in cash and cash equivalents | -29,582 | 10,360 | 15,568 |
Cash and cash equivalents, beginning of period | 64,480 | 54,120 | 38,552 |
Cash and cash equivalents, end of period | 34,898 | 64,480 | 54,120 |
Supplemental disclosures: | | | |
Increase in intercompany balances form the purchase of MediConnect and Argus by ISO | | | 773,174 |
Increase in intercompany balances from the purchase of treasury stock by Verisk funded directly by ISO | 0 | 0 | 0 |
Increase in intercompany balances from proceeds received by ISO related to issuance of Verisk common stock from options exercised | 0 | 0 | 0 |
Increase (decrease) in intercompany balances due to the merger of Verisk Health, Inc. | | -85,953 | |
Non-Guarantor Subsidiaries [Member] | Verisk Class A [Member] | | | |
Cash flows from financing activities: | | | |
Repurchases of Class A common stock | 0 | 0 | 0 |
Eliminating Entries [Member] | | | |
Schedule Of Condensed Consolidating Statement Of Cash Flows [Line Items] | | | |
Net cash provided by operating activities | 0 | 0 | 0 |
Cash flows from investing activities: | | | |
Acquisitions | 0 | 0 | 0 |
Purchase of non-controlling interest in non-public companies | 0 | | 0 |
Earnout payments | | | 0 |
Escrow funding associated with acquisitions | | | 0 |
Proceeds from release of acquisition related escrows | | 0 | 0 |
Proceeds from sale of subsidiary | 0 | | |
Investment in subsidiaries | 30,609 | 350 | |
Intercompany dividends received from subsidiaries | -114 | | |
Repayments received from other subsidiaries | -263,736 | | |
Repayments received from other subsidiaries | | -215,887 | -611,756 |
Advances provided to other subsidiaries | 5,075 | 98,692 | 52,000 |
Capital expenditures | 0 | 0 | 0 |
Purchases of available-for-sale securities | 0 | 0 | 0 |
Proceeds from sales and maturities of available-for-sale securities | 0 | 0 | 0 |
Other investing activities, net | | 0 | |
Net cash used in investing activities | -228,166 | -116,845 | -559,756 |
Cash flows from financing activities: | | | |
Repayments of current portion of long-term debt | | 0 | |
Proceeds from issuance of long-term debt, net of original issue discount | | | 0 |
Repayments of short-term debt refinanced on a long-term basis | | | 0 |
Proceeds (repayments) from short-term debt, net | 0 | 0 | 0 |
Proceeds from issuance of intercompany common stock | -30,609 | -350 | |
Intercompany dividends paid to subsidiaries | 114 | | |
Transfer of cash due to the Verisk Health, Inc. merger | | 0 | |
Repayments of advances to other subsidiaries | 263,736 | 215,887 | |
Advances received from other subsidiaries | -5,075 | -98,692 | -52,000 |
Payment of debt issuance costs | 0 | 0 | 0 |
Repayments of advances provided to other subsidiaries | | | 611,756 |
Excess tax benefits from exercised stock options | 0 | 0 | 0 |
Proceeds from stock options exercised | 0 | 0 | 0 |
Net share settlement of taxes from restricted stock awards | 0 | | |
Other financing activities, net | 0 | 0 | 0 |
Net cash (used in) provided by financing activities | 228,166 | 116,845 | 559,756 |
Effect of exchange rate changes | 0 | 0 | 0 |
(Decrease) increase in cash and cash equivalents | 0 | 0 | 0 |
Cash and cash equivalents, beginning of period | 0 | 0 | 0 |
Cash and cash equivalents, end of period | 0 | 0 | 0 |
Supplemental disclosures: | | | |
Increase in intercompany balances form the purchase of MediConnect and Argus by ISO | | | 0 |
Increase in intercompany balances from the purchase of treasury stock by Verisk funded directly by ISO | 0 | 0 | 0 |
Increase in intercompany balances from proceeds received by ISO related to issuance of Verisk common stock from options exercised | 0 | 0 | 0 |
Increase (decrease) in intercompany balances due to the merger of Verisk Health, Inc. | | 0 | |
Eliminating Entries [Member] | Verisk Class A [Member] | | | |
Cash flows from financing activities: | | | |
Repurchases of Class A common stock | $0 | $0 | $0 |